Panzyga (Immunoglobulin Intravenous (Human), 10%) Correct Coding and Coverage - Revised


December 4, 2019

Panzyga® (Immunoglobulin Intravenous (Human), 10%) is a sterile liquid preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma which has recently been approved by the FDA on August 2, 2018. Panzyga® is covered for claims with dates of service on or after August 2, 2018, when the criteria discussed below are met. Read the complete advisory article, Panzyga® (Immunoglobulin Intravenous (Human), 10%) Correct Coding and Coverage - Revised.


Last Updated: 12/04/2019

Palmetto GBA Web Chat

Sounds: OnSave Transcript
Please answer the questions below. Additional fields may appear based on previous answers. Fields with a red asterisk (*) are required.
Your InformationClear
1()-x
Inquiry InformationClear
Select your stateClear
Select your stateClear
Provider InformationClear
Patient InformationClear
Patient Name must exactly match the information submitted on the claim, including suffix if applicable.
//
Appeal InformationClear
//
//
Claim InformationClear
//
//
Denial InformationClear
//
//
Rejection InformationClear
DDE InformationClear
Restore InformationClear
//
Prior Authorization InformationClear
//
//
Application InformationClear
Product InformationClear
OtherClear
Additional InformationClear

Are you sure you want to end your chat?

Keep ChattingClose ChatSave Transcript & Close

Webchat

Our dedicated webchat representatives are online to assist you with your general inquiries, provider enrollment, EDI, eServices and more in real-time.